Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant human EGF-rP64K/Montanide ISA 51 vaccine

A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Center of Molecular Immunology (CIMA) epidermal growth factor (EGF) vaccine
Center of Molecular Immunology epidermal growth factor vaccine
CIMAvax EGF
CIMAvax epidermal growth factor vaccine
CimaVax vaccine
CIMAvax-EGF
recombinant human EGF-P64K/Montanide vaccine
Abbreviation:Cimavax
CimaVax
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search